A review of intralesional wart therapy

Muse, Mikel E.; Stiff, Katherine M; Glines, Katelyn R; Cline, Abigail; Feldman, Steven R.

doi:10.5070/d3263048027

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight subjects reported nine treatment‐related AEs: transient numbness which improved by Day 7 and was gone by Day 62 [ 3 ], suspected infection [ 3 ], pain during the procedure [ 2 ], and numbness and edema [ 1 ]. None of the AEs were severe and all had resolved by study end.…”

Section: Resultsmentioning

confidence: 99%

“…Current treatments for common and flat verrucae involve the destruction of the infected cells. Chemical approaches include daily topical salicylic acid [ 1 ], topical cantharidin [ 2 ], or intralesional injections of agents with immune activity [ 3 ] or cell‐killing activity [ 4 ]. Physical destruction modalities include freezing the verrucae with liquid nitrogen cryotherapy [ 5 ] and burning them off with electrodessication [ 6 ] or laser treatment [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)

Nuccitelli

LaTowsky

Lain³

et al. 2021

Lasers Surg Med

View full text Add to dashboard Cite

Background and Objectives This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non‐cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia. Study Design/Materials and Methods Sixty‐two subjects were enrolled at a total of five sites. One hundred and ninety‐five study verrucae up to 10 mm wide were treated with NPS delivered by a console‐based handheld applicator (CellFX® System; Pulse Biosciences) and follow‐ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant. Results Overall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120‐day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures. Conclusions NPS is a safe and effective procedure for removing non‐genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)

Nuccitelli

LaTowsky

Lain³

et al. 2021

Lasers Surg Med

View full text Add to dashboard Cite

show abstract

“…Cidofovir is an antiviral medication most commonly used to treat cytomegalovirus retinitis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). 6 Other off-label indications for its use include infections such as acyclovir-resistant herpes simplex virus infection, BK virus infection, adenovirus infection, and recurrent respiratory papillomatosis. Cidofovir can be administered intravenously, intralesionally, or topically depending on the clinical indication.…”

Section: Introductionmentioning

confidence: 99%

“…4 The lack of patient adherence to long treatment regimens and financial burdens associated with purchasing medication may also present significant barriers to appropriate care for individuals with cutaneous warts. 4 Various treatments for resistant warts have been explored, including cryotherapy, curettage/cautery, intralesional (IL) immunotherapy, laser therapy, intralesional bleomycin, cimetidine, and vitamin D. [4][5][6] In recent years, cidofovir has emerged as an option for treatment of refractory warts. Cidofovir is an antiviral medication most commonly used to treat cytomegalovirus retinitis in patients with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/ AIDS).…”

Section: Introductionmentioning

confidence: 99%

Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities

Lau

Frangos

et al. 2023

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Viral warts – manifestations of cutaneous infection by human papilloma virus – can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used for the treatment of cytomegalovirus infection, has emerged as an alternative treatment option for viral warts when administered topically or intralesionally. In this review, we highlight the scientific rationale, published evidence, and practical clinical uses of intralesional cidofovir for the management of cutaneous warts as well as ongoing questions requiring further research and exploration of this emerging therapy for refractory verrucae.

show abstract

“…Topical digoxin and furosemide have been used successfully for wart treatment in some cases and demonstrates clear and statistically significant pharmacodynamics effects with a favorable safety profile 9,10 . Intralesional therapy in warts treatment is better than topical application as it permits higher drug concentrations throughout the lesion so requires less number of sessions, no need for individual treatment of each wart, show promising efficacy, low or absent recurrence by increasing the local immune response with minimal adverse effects and trusting that the patient does not miss the dose and is recommended for multiple warts that are resistant to therapy, as well as warts that are in difficult‐to‐treat areas (ears, anogenital region) and hard‐to‐treat warts like palmar and plantar warts 1,11 . So, the aim of this study was to evaluate efficacy and safety of intralesional combined furosemide and digoxin in treatment of multiple cutaneous warts.…”

Section: Introductionmentioning

confidence: 99%

Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial

lofty

Elbakry

Omar

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Although being a benign lesion, Warts can affect the quality of life by causing discomfort, disfigurement, and social embarrassment besides the tendency to spread.Cutaneous wart treatment faces many challenges as the development of an antiviral drug that can eradicate the human papilloma virus (HPV) is difficult. This clinical study aimed to assess the efficacy and safety of intralesional combined furosemide and digoxin in the treatment of multiple cutaneous warts. This double blinded randomized clinical trial included 80 adult patients with multiple cutaneous warts (≥2 warts) who were randomized into two groups, Group I (40 patients) treated with intralesional combined furosemide and digoxin and Group II (40 patients) who were treated with intralesional normal saline solution as a control group, weekly till improvement or for maximum five sessions. Clinical and dermoscopic evaluation at baseline, every session, and monthly for 6 months after the last session to detect any recurrence was performed. Complete wart clearance was observed in 92.5% of patients in the intralesional combined furosemide and digoxin group (Group I) compared with 10.0% in saline group (Group II), with highly statistically significant difference (Pvalue = 0.000). Pain during injection in 95.0% and 45.0% of patients in Group I and Group II respectively, treatment group was superior compared to control group.Intralesional injection of combined furosemide and digoxin can be a safe and effective treatment option in multiple cutaneous warts with minimal side effects in this study.

show abstract

A review of intralesional wart therapy

Cited by 10 publications

References 0 publications

Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)

Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)

Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities

Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial

Contact Info

Product

Resources

About